Triptorelin
FDA-approved depot GnRH agonistEstablished
FDA-approved depot GnRH agonist (Trelstar) for advanced prostate cancer. Causes flare then downregulation of LH/testosterone. WADA S2.
For research use only.
Key Facts
- CAS
- 57773-63-4
- Molecular Weight (MW)
- —
- Half-life
- Depot: weeks to months
- Unit
- mg
- Administration Route
- Intramuscular
- Frequency
- Monthly to 24-week depot
- Last updated
- 8/23/2026
- Targets
- GnRH receptor
Overview
FDA-approved depot GnRH agonist (Trelstar) for advanced prostate cancer. Causes flare then downregulation of LH/testosterone. WADA S2.
Protocol
- Dosage Range
- Depot 3.75–22.5 mg IM on labeled intervals
- Frequency
- Monthly to 24-week depot
- Cycle
- Long-term ADT as prescribed
- Administration Route
- Intramuscular
- Reconstitution Guide
- —
Science
Mechanism of Action
Continuous GnRH-receptor stimulation suppresses gonadotropins after an initial flare, lowering sex steroids.
Targets
GnRH receptor
Studies
- Triptorelin androgen-deprivation therapy— Journal/year not available
Benefits
Labeled prostate-cancer ADT
Potential Side Effects
- Hot flashes
- Bone loss
- Tumor flare
- Injection-site reactions
References
- Trelstar labelExternal link · Year —
- WADA Prohibited List 2026External link · Year —